Understanding Real-Life Response to Lurbinectedin as Second Line Therapy in Patients with Extensive Stage Small-Cell Lung Cancer

被引：0
|
作者：
Curt, K. [1 ]
Rice, J. [1 ]
Qin, A. [1 ]
机构：
[1] Univ Michigan, Ann Arbor, MI USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
Lurbinectedin; Real-life efficacy; Extensive Stage Small Cell Lung Cancer;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP13.07-01
引用
收藏
页码：S705 / S706
页数：2
相关论文
共 50 条
  • [1] Real-World Outcomes with Lurbinectedin in Second Line and Beyond for Extensive Stage Small Cell Lung Cancer in Korea
    Shim, Joo Sung
    Kim, Youhyun
    Yuh, Taeho
    Lee, Jii Bum
    Kim, Hye Ryun
    Hong, Min Hee
    Cho, Byoung Chul
    Lim, Sun Min
    LUNG CANCER-TARGETS AND THERAPY, 2024, 15 : 149 - 159
  • [2] Real-World Outcomes With Lurbinectedin in Second-Line Setting and Beyond for Extensive Stage Small Cell Lung Cancer
    Desai, Aakash
    Smith, Caleb J.
    Ashara, Yash
    Orme, Jacob J.
    Zanwar, Saurabh
    Potter, Ashley
    Hocum, Craig
    Moffett, J. Nicole
    Schwecke, Anna J.
    Manochakian, Rami
    Lou, Yanyan
    Zhao, Yujie
    Ernani, Vinicius
    Savvides, Panos
    Molina, Julian
    Dimou, Anastasios
    Mansfield, Aaron S.
    Parikh, Kaushal
    Leventakos, Konstantinos
    CLINICAL LUNG CANCER, 2023, 24 (08) : 689 - +
  • [3] Second-line therapy for small-cell lung cancer
    Schmittel, Alexander
    EXPERT REVIEW OF ANTICANCER THERAPY, 2011, 11 (04) : 631 - 637
  • [4] Extensive-Stage Small-Cell Lung Cancer: First-Line and Second-Line Treatment Options
    Zugazagoitia, Jon
    Paz-Ares, Luis
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06) : 671 - +
  • [5] Radiotherapy for extensive stage small-cell lung cancer
    McKay, Michael J.
    LANCET, 2015, 385 (9975): : 1291 - 1292
  • [6] Subsequent Systemic Therapy After Lurbinectedin Discontinuation in Patients With Small-cell Lung Cancer
    Subbiah, V.
    Paz-Ares, L.
    Besse, B.
    Zaman, K.
    Sala, M. A.
    Fernandez, C.
    Siguero, M.
    Kahatt, C.
    Lopez-Vilarino, J. A.
    Zeaiter, A.
    Arrondeau, J.
    Delord, J.
    Martinez, M.
    Wannesson, L.
    Anton, A.
    Trigo, J. M.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S937 - S938
  • [7] A pivotal bridging study of lurbinectedin as second-line therapy in Chinese patients with small cell lung cancer
    Cheng, Ying
    Wu, Chunjiao
    Wu, Lin
    Zhao, Jun
    Zhao, Yanqiu
    Chen, Lulu
    Xin, Ying
    Zhang, Liang
    Pan, Pinhua
    Li, Xingya
    Li, Juan
    Dong, Xiaorong
    Tang, Ke
    Gao, Emei
    Yu, Fei
    SCIENTIFIC REPORTS, 2024, 14 (01)
  • [8] A pivotal bridging study of lurbinectedin as second-line therapy in Chinese patients with small cell lung cancer
    Ying Cheng
    Chunjiao Wu
    Lin Wu
    Jun Zhao
    Yanqiu Zhao
    Lulu Chen
    Ying Xin
    Liang Zhang
    Pinhua Pan
    Xingya Li
    Juan Li
    Xiaorong Dong
    Ke Tang
    Emei Gao
    Fei Yu
    Scientific Reports, 14
  • [9] A retrospective real-world experience of immunotherapy in patients with extensive stage small-cell lung cancer
    Qiu, Guihuan
    Wang, Fei
    Xie, Xiaohong
    Liu, Ting
    Zeng, Chen
    Chen, Ziyao
    Zhou, Maolin
    Deng, Haiyi
    Yang, Yilin
    Lin, Xinqing
    Xie, Zhanhong
    Sun, Gengyun
    Zhou, Chengzhi
    Liu, Ming
    CANCER MEDICINE, 2023, 12 (14): : 14881 - 14891
  • [10] Real-life second-line epirubicin-paclitaxel regimen as treatment of relapsed small-cell lung cancer: EpiTax study
    Annic, Josselin
    Babey, Helene
    Corre, Romain
    Descourt, Renaud
    Quere, Gilles
    Renaud, Emmanuelle
    Lambert, Mickael
    Le Noac'h, Pierre
    Dhamelincourt, Estelle
    Nguyen, Jessica
    Vu, Alicia
    Bourbonne, Vincent
    Robinet, Gilles
    Geier, Margaux
    CANCER MEDICINE, 2023, 12 (03): : 2658 - 2665
12345